

PROGRAMME



CANCER CARE FOR ALL:

Understanding
Populations to
Improve Outcomes



PROGRAMME

10.00 - 11.00	Delegate registration opens with refreshments and poster exhibition
11.00 - 11.10	Welcome address <i>Delivered by Ms Sara Long</i> Regional Executive Officer for HSE Dublin and North East
SESSION ONE	
CHAIR: Professor Patrick G. Morris MD, FRCPI Medical Director, Beaumont RCSI Cancer Centre	
11.10 - 11.50	Testing for possible cancer; the WHO and the HOW? <i>Delivered by Professor Willie Hamilton, CBE, MD, FRCP, FRCGP</i> Professor of Primary Care Diagnostics, University of Exeter and Cancer Research UK
11.50 - 12.25	Transitions in chronic disease epidemiology and what they mean for population cancer risk <i>Delivered by Professor Edward W. Gregg PhD</i> Professor and Head of School, RCSI University of Medicine and Health Sciences
12.25 - 13.00	Recent innovations in lung cancer: precision medicine, immunotherapy and early detection <i>Delivered by Professor Jarushka Naidoo</i> Professor of Medical Oncology and Consultant Medical Oncologist, Beaumont Hospital and RCSI University of Medicine and Health Sciences
13.00 - 13.40	Refreshments and poster exhibition
SESSION TWO	
CHAIR: Professor Leonie Young Professor, Scientific Director Beaumont RCSI Cancer Centre	
13.45 - 14.20	Opinion is the lowest form of evidence - data informed intelligence to shift the dial on cancer <i>Delivered by Professor Mark Lawler</i> Professor of Digital Health, Queen's University Belfast, Chair of the Lancet Oncology European Groundshot Commission, and Chair of the International Cancer Benchmarking Partnership
14.20 - 14.55	Patient/public involvement in cancer clinical research, patient perspectives from an Irish metastatic breast cancer patient <i>Delivered by Ms Siobhan Gaynor</i> Patient Consultative Committee member, Cancer Trials Ireland
14.55 - 15.30	Panel discussion with all speakers <i>Chaired by Professor Leonie Young</i> Professor, Scientific Director Beaumont RCSI Cancer Centre
15.30	END

SPEAKERS



Professor Willie Hamilton

Willie Hamilton, CBE, MD, FRCP, FRCGP, is professor of primary care diagnostics at University of Exeter.

The major part of his work is in cancer diagnostics in the symptomatic patient – the one sitting in the GP's consulting room. He leads the DISCOVERY team, with staffing varying from 10-18, plus 4 PhD students, all supported by his grant awards. These grants total over £67m, including CRUK's first Catalyst award.

He has published approaching 400 papers, including the 2010 and 2015 overall Research Paper of the Year for studies on ovarian cancer and on the public appetite for cancer testing. He also was the cancer category winner in 2013, 2014, 2016 and 2017. He was clinical lead on the UK's NICE guidance on suspected cancer, NG12, published in 2015. This governs over £1bn of annual NHS spending.

He was awarded a CBE in the 2019 New Years' Honours List for services to improving early cancer diagnosis.

SPEAKERS



Professor Edward W. Gregg

Edward W. Gregg is Professor and Head of the recently launched RCSI School of Population Health, which aims to guide the key decisions in health policies, promotion, and health services through science, education, and collaborations. He also holds a joint appointment as Professor and Chair in Diabetes and Cardiovascular Disease Epidemiology in the School of Public Health. Before that he led a multi-disciplinary public health research unit for chronic diseases at the US Centers for Disease Control Prevention.

He has worked extensively in chronic disease epidemiology and surveillance, prevention effectiveness trials, the development of natural experiments to study health policies, and modelling of health impact and cost-effectiveness of public health interventions. His research has focused on understanding the causes, dynamics, and prevention of diabetes and its complications, and includes long-term follow-up studies of the lifestyle interventions as well as the evaluation of US and UK-based public health prevention programmes.

He has led and served in numerous health policy development roles for diabetes and chronic diseases for organizations such as the World Health Organization, Lancet Commission, US CDC, and American Diabetes Association. He has published more than 380 peer reviewed articles and chapters and was awarded the ADA 2016 Kelly West Award for Excellence in Diabetes Epidemiology and the International Diabetes Federation (IDF) 2015 award for Epidemiology award for Epidemiology.

SPEAKERS



Professor Jarushka Naidoo

Professor Jarushka Naidoo is a Full Professor of Medical Oncology and a Consultant Medical Oncologist at Beaumont RCSI Cancer Centre in Dublin, Ireland and an Adjunct Professor of Oncology at Johns Hopkins University.

Professor Naidoo graduated with her medical degree (MB BCh BAO) from Trinity College Dublin, and completed internal medicine and a medical oncology training through the Royal College of Physicians of Ireland. She completed an awarded advanced medical oncology fellowship at Memorial Sloan Kettering Cancer Center (New York), and joined the faculty at Johns Hopkins University from 2015-2020. At Johns Hopkins, she led a portfolio of clinical trials and translational studies focused on immunotherapy for lung cancer and immune-related toxicity. Professor Naidoo led several investigator-initiated trials for patients with lung cancer, with a focus on stage III non-small lung cancer and CNS metastases. She is a globally recognised leader in the field of immune-related toxicity, with >100 publications in this field, and her development of the multidisciplinary Johns Hopkins Immune-related Toxicity Team. She is the recipient of several grants and awards including a US NIH KL2 Clinical Scholar Award, Lung Cancer Foundation of America/IASLC Young Investigator Award.

Since her return to Ireland, she serves as the Chair of the Lung Cancer Disease-specific subgroup (DSSG) of Cancer Trials Ireland, is the Founder and Chair of the Irish national lung cancer research group, the 'Irish Lung Cancer Alliance,' and a national immunotherapy toxicity network through the RCPI. She is currently a part of the ETOP, EORTC, ECOG-ACRIN and NRG Cooperative clinical trial groups, and the clinical trials portfolio in lung cancer has tripled since her return. Professor Naidoo was named the Irish Cancer Society's Clinician Research Leader Award 2021.

SPEAKERS



Professor Mark Lawler

Professor Mark Lawler is Professor of Digital Health and Chair in Translational Cancer Genomics at Queen's University Belfast. He is Co-lead of the All Island Cancer Research Institute (AICRI). He is Scientific Director of DATA-CAN, the UK's Health Data Research Hub for Cancer. Mark is Chair of the International Cancer Benchmarking Partnership, which sets a benchmark for cancer outcomes globally. He is Chair of the Lancet Oncology European Groundshot Commission, the most comprehensive analysis of cancer research in Europe ever, which reimagines cancer research and its implementation across Europe.

Mark has a strong commitment to patient-centred research and addressing cancer inequalities. He was architect of the European Cancer Patient's Bill of Rights, launched in the European Parliament (World Cancer Day). He received the 2018 European Health Award, a prestigious award for partnerships that yield real health impact in Europe. His pioneering work on Covid-19 and cancer received the Royal College of Physicians Excellence in Patient Care Award and the prestigious European Communique Award, which recognised the use of data to enhance cancer services and effect policy change.

He leads the European Cancer Organisation's European Cancer Pulse which captures data intelligence to inform mitigation of cancer inequalities. In 2021, Mark received the Irish Association for Cancer Research's Outstanding Contribution to cancer research award, for his pioneering work on cancer research and care on the island of Ireland. In 2022, he and his team won the prestigious HDR-UK Impact of the Year Award for providing the crucial health economic intelligence to inform a change in policy for treating colorectal cancer.

Recently Professor Lawler's group published the most comprehensive analysis of the costs of precision oncology drugs on the market, highlighting how a companion diagnostic informed precision oncology approach is more cost effective than a one size fits all approach in cancer. Professor Lawler was one of the leadership involved in developing and launching a radical new plan for cancer research and cancer care in the House of Commons. In November 2023, Professor Lawler received a Special Merit Award from the European Cancer Organisation, Europe's largest multi-professional cancer organisation, in recognition of his ground-breaking work in Covid and Cancer and his work on cancer inequalities.

SPEAKERS



Siobhan Gaynor

I was diagnosed with primary breast cancer in May 2019 and then in October 2020, I was diagnosed with metastatic (secondary/advanced/Stage IV) breast cancer (MBC). I had started to experience back pain and fatigue.

“When I was diagnosed with primary breast cancer, and having worked in the field, my knowledge really helped to accept and understand it quite quickly.

However, metastatic cancer was completely different and it forced changes to my life. I had to medically retire after 31 years of working in medicines research and development, due to symptoms of the disease, and also the fact that metastatic breast cancer is a disease that is life limiting. I volunteer on a number of cancer research committees and am also planning a few trips and making memories with family and friends.”

Most Stage IV cancers are incurable, although thanks to science and research we are now living longer and the challenge has moved to focus on quality of life aspects. I felt that a survey, with patient input from Irish Stage IV cancer patients was needed.

This MBC survey was launched via Cancer Trials Ireland in July 2023 and in less than 3 months 246 Irish MBC patients fully completed the online survey. The results of the survey will be published shortly.

SPONSORS



AMGEN[®]



AstraZeneca 



 **Pfizer**



Janssen 
PHARMACEUTICAL COMPANIES OF
Johnson & Johnson



 **MSD**



 **NOVARTIS**



novocure[®]



**B
A
Y
E
R**



**EXACT
SCIENCES**

Exact Sciences Ireland, Ltd. has had no input or influence on the agenda



RCSI

RCSI Royal College of Surgeons in Ireland
123 St Stephen's Green, Dublin 2
Tel: +353 1 402 2100
Email: events@rcsi.com
rcsi.com



**BEAUMONT RCSI
CANCER CENTRE**

Beaumont RCSI Cancer Centre
Beaumont Hospital Campus,
Beaumont Road, Dublin 9.
Tel: +353 1 809 3000

CONFERENCE GUEST WIFI

Select RCSI-GUEST

Log in using the following details:

Password: RC\$1guest